Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Novartis - Statistics & Facts

In 2019, Swiss-based Novartis was the second largest pharmaceutical company worldwide based on revenue from prescription drugs. In 2020, Novartis made some 48.7 billion U.S. dollars of revenue in total, a slight decrease compared to the previous year, which was mostly due to the spin-off of its eye care division Alcon. The company made some significant restructuring measures since 2015, so that today there are only two major core businesses left.

Novartis is divided into two segments: Pharmaceuticals (now called Innovative Medicines), and Sandoz. The Pharmaceuticals segment is responsible for the largest part of the total revenue – around 39 billion U.S. dollars. From a regional point of view, Novartis generates the overwhelming part of its revenue in the United States and in Europe. In 2020, about 18.7 billion U.S. dollars were generated in Europe and some 16.5 billion dollars in the United States. Among Novartis’ top products are immunomodulating drug Gilenya and ophthalmic drug Lucentis. It is estimated that Novartis reaches around 770 million people worldwide through its products.

Nearly nine billion U.S. dollars – almost 19 percent of Novartis’ total revenue – was spent on research and development in 2020. R&D is a major issue for the top pharmaceutical companies because patent expiration can lead to massive revenue losses. Thus, only new medicines with at least a few years of exclusivity can ensure progress and profit. At Novartis, such growth products make up around one third of its total revenues.

Key figures

The most important key figures provide you with a compact summary of the topic of "Novartis" and take you straight to the corresponding statistics.

Company Overview

Research and Development

Interesting statistics

In the following 5 chapters, you will quickly find the {amountStatistics} most important statistics relating to "Novartis".

Novartis

Dossier on the topic

All important statistics are prepared by our experts – available for direct download as PPT & PDF!
TOP SELLER

Novartis - Statistics & Facts

In 2019, Swiss-based Novartis was the second largest pharmaceutical company worldwide based on revenue from prescription drugs. In 2020, Novartis made some 48.7 billion U.S. dollars of revenue in total, a slight decrease compared to the previous year, which was mostly due to the spin-off of its eye care division Alcon. The company made some significant restructuring measures since 2015, so that today there are only two major core businesses left.

Novartis is divided into two segments: Pharmaceuticals (now called Innovative Medicines), and Sandoz. The Pharmaceuticals segment is responsible for the largest part of the total revenue – around 39 billion U.S. dollars. From a regional point of view, Novartis generates the overwhelming part of its revenue in the United States and in Europe. In 2020, about 18.7 billion U.S. dollars were generated in Europe and some 16.5 billion dollars in the United States. Among Novartis’ top products are immunomodulating drug Gilenya and ophthalmic drug Lucentis. It is estimated that Novartis reaches around 770 million people worldwide through its products.

Nearly nine billion U.S. dollars – almost 19 percent of Novartis’ total revenue – was spent on research and development in 2020. R&D is a major issue for the top pharmaceutical companies because patent expiration can lead to massive revenue losses. Thus, only new medicines with at least a few years of exclusivity can ensure progress and profit. At Novartis, such growth products make up around one third of its total revenues.

Interesting statistics

In the following 5 chapters, you will quickly find the {amountStatistics} most important statistics relating to "Novartis".

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Hadley Ward
Hadley Ward
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Ziyan Zhang
Ziyan Zhang
Customer Relations– Contact (Asia)

Mon - Fri, 11:30am - 10pm (IST)

Contact Kisara Mizuno
Kisara Mizuno
Customer Success Manager– Contact (Asia)

Mon - Fri, 9:30am - 5:30pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Catalina Rodriguez
Catalina Rodriguez
Key Account Manager - LAC– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)